Acrylic Polymer Matrix for Levonorgestrel Transdermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal delivery systems for levonorgestrel and ethinyl estradiol face challenges such as high delivery rates, patch size issues, and difficulty in achieving sustained drug delivery over 7 days, with no commercial combination product available, due to factors like crystallization and formulation complexity.
Innovation Solution
A transdermal drug delivery system comprising a polymer matrix with levonorgestrel, ethinyl estradiol, and an acrylic polymer, potentially including glyceryl monooleate or dipropylene glycol as penetration enhancers, which is free or substantially free of polyvinylpyrrolidone, allowing for sustained delivery over 3 to 7 days without crystallization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional transdermal delivery systems are used for levonorgestrel and ethinyl estradiol, then drug delivery can be achieved, but sustained delivery over 7 days is difficult to accomplish
Solution Approach 1:
The patent changes the chemical composition parameters of the polymer matrix by formulating with specific ratios of levonorgestrel (0.1-5%), ethinyl estradiol (0.1-5%), and acrylic polymer (94.9-90.0%), along with penetration enhancers (5-20%), to achieve sustained delivery over 7 days. This parameter optimization resolves the contradiction between delivery duration and reliability.
Solution Approach 2:
The patent creates a composite polymer matrix system combining multiple components: levonorgestrel, ethinyl estradiol, acrylic polymer, and penetration enhancers (such as glyceryl monooleate or dipropylene glycol). This composite formulation enables sustained delivery by controlling the release kinetics of each component through their synergistic interactions.
2Duration of action of moving object
If high drug loading is used to extend delivery duration, then delivery duration improves, but crystallization occurs reducing stability
Solution Approach 1:
The patent optimizes the concentration parameters of levonorgestrel (0.1-5%) and ethinyl estradiol (0.1-5%) within specific ranges that prevent crystallization while maintaining sustained delivery capability. The acrylic polymer content (94.9-90.0%) is also precisely controlled to provide sufficient matrix structure that inhibits crystal formation.
Solution Approach 2:
The patent introduces penetration enhancers (glyceryl monooleate or dipropylene glycol) as intermediary substances that act as crystallization inhibitors. These enhancers modify the physical state of the drug molecules within the polymer matrix, preventing crystallization while facilitating drug release over 7 days.
3Ease of operation
If conventional adhesive polymer matrices are used, then adhesion is achieved, but formulation complexity increases due to multiple required components
Solution Approach 1:
The patent employs an acrylic polymer matrix that simultaneously provides adhesion, drug solubility, and crystallization inhibition in a single component system. This multi-functional polymer eliminates the need for separate adhesive layers and crystallization inhibitors, reducing formulation complexity while maintaining ease of operation.
Solution Approach 2:
The patent merges multiple functions into a single integrated formulation: the acrylic polymer matrix combines adhesive properties, drug carrier capabilities, penetration enhancer functions, and crystallization prevention in one unified system, simplifying the overall formulation while achieving all required performance criteria.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves sustained delivery of levonorgestrel and ethinyl estradiol for extended periods, reducing crystallization and improving stability, as demonstrated by in vitro flux studies compared to commercial products like Climara Pro and OrthoEvra.
Implementation Method 1
the polymer matrix may comprise 5 to 20% penetration enhancer. In any embodiments, the penetration enhancer may be glyceryl monooleate, dipropylene glycol, or mixtures thereof
Data Source
AI summary
Described are transdermal drug delivery systems for the transdermal administration of levonorgestrel and ethinyl estradiol, comprising an acrylic polymer matrix. Methods of making and using such systems also are described.